Tag: Synta Pharmaceuticals Corp.

Finance

Investor’s Alert: Inovio Pharmaceuticals (NYSEMKT:INO), Synta Pharmaceuticals (NASDAQ:SNTA), Repligen Corporation (NASDAQ:RGEN), Agios Pharmaceuticals (NASDAQ:AGIO)

Inovio Pharmaceuticals Inc (NYSE:INO) CEO Jong Joseph Kim bought 25,000 shares of the company’s stock in a transaction dated Tuesday, April 15th. The shares were purchased at an average price of $2.25 per share, for a total transaction of $56,250.00. Inovio Pharmaceuticals Inc (NYSEMKT:INO) stock performance was -2.62% in last session and finished the day at $2.60. Traded volume was 16.17million shares in the last … Continue reading Investor’s Alert: Inovio Pharmaceuticals (NYSEMKT:INO), Synta Pharmaceuticals (NASDAQ:SNTA), Repligen Corporation (NASDAQ:RGEN), Agios Pharmaceuticals (NASDAQ:AGIO)

John Bellich
Finance

Healthcare Bullish Stocks: Synta Pharmaceuticals (NASDAQ:SNTA), TherapeuticsMD Inc (NYSEMKT:TXMD), Cell Therapeutics Inc (NASDAQ:CTIC), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Synta Pharmaceuticals Corp. (NASDAQ:SNTA) announced that poster presentations related to studies with ganetespib, a selective Hsp90 inhibitor in clinical development by the company, and the company’s Hsp90 inhibitor drug conjugates (HDC) will be presented at the 2014 Annual Meeting of the American Association of Cancer Research in San Diego, California. Synta Pharmaceuticals Corp. (NASDAQ:SNTA) stock performance was 10.07% in last session and finished the day … Continue reading Healthcare Bullish Stocks: Synta Pharmaceuticals (NASDAQ:SNTA), TherapeuticsMD Inc (NYSEMKT:TXMD), Cell Therapeutics Inc (NASDAQ:CTIC), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Colin Pettis
BioTech

Biotech Volatile Stocks: CytRx Corporation (NASDAQ:CYTR), Synta Pharmaceuticals (NASDAQ:SNTA), Idenix Pharmaceuticals (NASDAQ:IDIX), CEL-SCI Corporation (NYSEMKT:CVM)

Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of purchasers of CytRx Corporation (NASDAQ:CYTR) common stock during the period between November 22, 2013 and March 13, 2014, inclusive (the “Class Period”). CytRx Corporation (NASDAQ:CYTR) stock performance was 0.00% in last session and finished the day … Continue reading Biotech Volatile Stocks: CytRx Corporation (NASDAQ:CYTR), Synta Pharmaceuticals (NASDAQ:SNTA), Idenix Pharmaceuticals (NASDAQ:IDIX), CEL-SCI Corporation (NYSEMKT:CVM)

John Bellich